Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Defining secondary progressive multiple sclerosis.
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis,...
متن کاملSpotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing-remittin...
متن کاملGreater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease.
The pathological substrate of progressive disability in multiple sclerosis is hypothesized to be axonal loss. Differences in the demographic, pathological and radiological features of patients with primary progressive compared with secondary progressive multiple sclerosis raise the question as to whether they actually represent separate clinical entities. So far, large pathological studies comp...
متن کاملThe natural history of secondary progressive multiple sclerosis.
BACKGROUND The onset of secondary progression is a pivotal event in the course of relapsing-remitting (RR) multiple sclerosis (MS). Patients with secondary progressive MS (SPMS) experience continuous worsening of symptoms independent of the occurrence of relapses. Possible risk factors associated with the onset of SPMS remain under investigated in natural history studies of MS disease course. ...
متن کاملBeta‐interferon exposure and onset of secondary progressive multiple sclerosis
BACKGROUND AND PURPOSE Beta-interferons (IFNβ) are the most widely prescribed drugs for patients with multiple sclerosis (MS). However, whether or not treatment with IFNβ can delay secondary progressive MS (SPMS) onset remains unknown. Our aim was to examine the association between IFNβ exposure and SPMS onset in patients with relapsing-remitting MS (RRMS). METHODS A retrospective cohort stud...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CNS Drugs
سال: 2021
ISSN: 1172-7047,1179-1934
DOI: 10.1007/s40263-020-00785-7